Table 3

Parameter estimates from the linear regression model for total cholesterol
Adjusted R2= 0.44 Cholesterolpre-treated (N = 1286)
Covariates β (95% CI) P-value
Cholesterolpost-treated (mg/dl) 0.53 (0.46,0.60) <.001
Age (years) -0.18 (-0.35,-0.01) 0.033
Gender – Male -10.32 (-13.66,-6.98) <.001
Race/ethnicity
White -- -- --
Chinese -6.21 (-11.71,-0.72) 0.027
Black -7.62 (-11.63,-3.60) <.001
Hispanic -1.21 (-5.32,2.90) 0.565
Diabetes
Normal -- -- --
IFG 0.23 (-3.80,4.26) 0.910
Untreated diabetes 2.69 (-9.46,14.85) 0.664
Treated diabetes -9.00 (-12.91,-5.10) <.001
Hypertension Meds – Yes -5.43 (-8.79,-2.08) 0.002
HDLpost-treated 0.12 (-0.03,0.26) 0.107
triglycerides 0.03 (-0.00,0.05) 0.069
Atorvastatin
Yes – Low dose 28.31 (18.19,38.42) <.001
Yes – High dose 42.84 (31.99,53.69) <.001
Fluvastatin
Yes – Low dose 18.24 (1.01,35.47) 0.038
Yes – High dose 25.83 (13.15,38.51) <.001
Lovastatin
Yes – Low dose 19.41 (8.61,30.21) <.001
Yes – High dose 34.80 (20.87,48.74) <.001
Pravastatin
Yes – Low dose 20.23 (8.69,31.77) 0.001
Yes – High dose 23.72 (8.71,38.73) 0.002
Simvastatin
Yes – Low dose 45.46 (22.98,67.94) <.001
Yes – High dose 19.16 (-16.64,54.96) 0.294
Simvastatin*Cholesterolpost-treated Interaction
Yes – Low dose -0.12 (-0.25,0.01) 0.071
Yes – High dose 0.11 (-0.11,0.32) 0.320
Rosuvastatin – Yes 38.36 (26.43,50.29) <.001
Fibrate – Yes 7.00 (-3.76,17.77) 0.202
Resin – Yes -7.76 (-31.48,15.96) 0.521
Niacin – Yes -29.12 (-56.25,-2.00) 0.035
Niacin*Cholesterolpost-treated Interaction 0.12 (-0.02,0.27) 0.101
Ezetimibe – Yes 12.10 (2.27,21.94) 0.016

Jorgensen et al.

Jorgensen et al. BMC Medical Research Methodology 2013 13:81   doi:10.1186/1471-2288-13-81

Open Data